Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTavitiya Sudjaritruken_US
dc.contributor.authorLinda Aurpibulen_US
dc.contributor.authorPenh Sun Lyen_US
dc.contributor.authorThoa Phan Kim Leen_US
dc.contributor.authorTorsak Bunupuradahen_US
dc.contributor.authorRawiwan Hansudewechakulen_US
dc.contributor.authorPagakrong Lumbiganonen_US
dc.contributor.authorKulkanya Chokephaibulkiten_US
dc.contributor.authorNik Khairulddin Nik Yusoffen_US
dc.contributor.authorLam Van Nguyenen_US
dc.contributor.authorKamarul Azahar Mohd Razalien_US
dc.contributor.authorMoy Siew Fongen_US
dc.contributor.authorRevathy A. Nallusamyen_US
dc.contributor.authorNia Kurniatien_US
dc.contributor.authorViet Chau Doen_US
dc.contributor.authorDavid C. Boettigeren_US
dc.contributor.authorAnnette H. Sohnen_US
dc.contributor.authorAzar Kariminiaen_US
dc.description.abstract© 2017 Society for Adolescent Health and Medicine Purpose To assess the incidence and predictors of postsuppression virologic rebound (VR) among adolescents on stable combination antiretroviral therapy in Asia. Methods Perinatally HIV-infected Asian adolescents (10–19 years) with documented virologic suppression (two consecutive viral loads [VLs] <400 copies/mL ≥6 months apart) were included. Baseline was the date of the first VL <400 copies/mL at age ≥10 years or the 10th birthday for those with prior suppression. Cox proportional hazards models were used to identify predictors of postsuppression VR (VL >1,000 copies/mL). Results Of 1,379 eligible adolescents, 47% were males. At baseline, 22% were receiving protease inhibitor–containing regimens; median CD4 cell count (interquartile range [IQR]) was 685 (448–937) cells/mm3; 2% had preadolescent virologic failure (VF) before subsequent suppression. During adolescence, 180 individuals (13%) experienced postsuppression VR at a rate of 3.4 (95% confidence interval: 2.9–3.9) per 100 person-years, which was consistent over time. Median time to VR during adolescence (IQR) was 3.3 (2.1–4.8) years. Wasting (weight-for-age z-score <−2.5), being raised by grandparents, receiving second-line protease inhibitor–based regimens, starting combination antiretroviral therapy after 2005, and having preadolescent VF were independent predictors of adolescent VR. At VR, median age, CD4 cell count, and VL (IQR) were 14.8 (13.2–16.4) years, 507 (325–723) cells/mm3, and 4.1 (3.5–4.7) log10copies/mL, respectively. Conclusions A modest and consistent incidence of postsuppression VR was documented during adolescence in our cohort. Having poor weight, receiving second-line regimens, and prior VF were associated with an increased VR rate. Adolescents at higher risk of VR may benefit from more intensive VL monitoring to enhance adherence management.en_US
dc.titleIncidence of Postsuppression Virologic Rebound in Perinatally HIV-Infected Asian Adolescents on Stable Combination Antiretroviral Therapyen_US
article.title.sourcetitleJournal of Adolescent Healthen_US
article.volume61en_US Mai Universityen_US Center for HIV/AIDSen_US's Hospital 1en_US HIV Netherlands Australia Thailand Research Collaborationen_US Prachanukroh Hospitalen_US Kaen Universityen_US Universityen_US Raja Perempuan Zainab IIen_US Hospital of Pediatrics Hanoien_US Lumpur Hospitalen_US Likasen_US Hospitalen_US of Indonesia, RSUPN Dr. Cipto Mangunkusumoen_US's Hospital 2en_US of New South Wales (UNSW) Australiaen_US for AIDS Researchen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.